Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
Long‐term Depot Neuroleptic Treatment With Perphenazine Decanoate I
In an open , prospect i ve 12 month study of perphenazine decanoate (  PD )  , 42 psyhchotic patients diagnosed according to DSM‐III were treated with a fixed depot interval and an individual dose , guided by gas chromatographic perphenazine plasma concentration monitoring combined with clinical evaluation . Degree of illness was rated using a social‐psychiatric CGI‐scale and extrapyramidal side effects were evaluated by means of a modified Simpson and Angus rating scale . After six months of treatment , a statistically significant improvement was found ( p < 0.001 ) . During the last six months a further slight reduction in mean CGI‐scores was observed . Mild to moderate extrapyramidal side effects occurred in 9 patients ( 21 % ) principally during the initial phase of therapy . No other side effects or changes in blood chemistry were found during the study . Plasma concentrations of perphenazine increased during the initial 3 months and stabilized hereafter . There were however , large intra‐ and inter‐individual variations in the perphenazine plasma concentration/dose ratio . In addition , it was observed that plasma concentrations of perphenazine were significantly higher in patients who had been treated with neuroleptics for more than 10 years compared to those who had been treted 5 years or less . This observation indicates gradual development of tolerance to neuroleptic treatment
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .